|Bid||0.00 x 305200|
|Ask||0.00 x 800|
|Day's Range||29.98 - 30.00|
|52 Week Range||23.56 - 30.00|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
"We are really beginning to see a shift toward using innovative telehealth solutions to help improve patient outcomes with home dialysis," said Dr. Michael Kraus, Associate Chief Medical Officer for NxStage. "Nx2me is an intuitive tool to support and proactively engage with home hemodialysis patients. A key component of the Nx2me platform is the Nx2me iPad® app, which is designed to increase patients' ease of use of home therapy by capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets.
Patients 20-44 years of age experienced 44% lower risk of death LAWRENCE, Mass. , Oct. 23, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing ...
LAWRENCE, Mass., Oct. 18, 2018 /PRNewswire/ -- NxStage Medical, Inc. (NXTM), a leading medical technology company focused on advancing renal care, announced new findings demonstrating significant survival benefit and lower cardiovascular hospitalization with more frequent home hemodialysis using the NxStage® System One™ within the skilled nursing facility setting. The data, developed in collaboration with Affiliated Dialysis Centers, LLC, will be presented by NxStage at the American Society of Nephrology (ASN) Kidney Week 2018 Annual Meeting on October 26th. Conference attendees can meet with NxStage representatives at booth 1841 to discuss the recent findings.
WallStEquities.com scans Illumina Inc. (NASDAQ: ILMN), Intuitive Surgical Inc. (NASDAQ: ISRG), Merit Medical Systems Inc. (NASDAQ: MMSI), and Nxstage Medical Inc. (NASDAQ: NXTM). Companies in the Medical Instruments and Supplies manufacturing industry primarily research, develop, and produce nonelectronic medical, surgical, dental and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps, and medical thermometers.All you have to do is sign up today for this free limited time offer by clicking the link below.
Ahead of today's trading session, WallStEquities.com features the Medical Instruments and Supplies manufacturing industry, which primarily researches, develops, and produces nonelectronic medical, surgical, dental, and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, and blood transfusion equipment.Under evaluation this morning are these four stocks: Mazor Robotics Ltd (NASDAQ: MZOR), Merit Medical Systems Inc. (NASDAQ: MMSI), Nxstage Medical Inc. (NASDAQ: NXTM), and Sientra Inc. (NASDAQ: SIEN). All you have to do is sign up today for this free limited time offer by clicking the link below.
Stock Research Monitor: ILMN, NXTM, and SIEN LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on VLRX sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...
Stock Monitor: Milestone Scientific Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 17, 2018 / Active-Investors.com has just released a free research report on Nxstage Medical, Inc. (NASDAQ: NXTM ...
Innovative AVF needle guard includes enhancements designed to prevent needlesticks LAWRENCE, Mass. , April 13, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company ...